U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H48O4
Molecular Weight 472.7009
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEDERAGENIN

SMILES

CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@]4([H])[C@@]5(C)CC[C@@]([H])([C@@](C)(CO)[C@]5([H])CC[C@]43C)O)[C@]2([H])C1)C(=O)O

InChI

InChIKey=PGOYMURMZNDHNS-MYPRUECHSA-N
InChI=1S/C30H48O4/c1-25(2)13-15-30(24(33)34)16-14-28(5)19(20(30)17-25)7-8-22-26(3)11-10-23(32)27(4,18-31)21(26)9-12-29(22,28)6/h7,20-23,31-32H,8-18H2,1-6H3,(H,33,34)/t20-,21+,22+,23-,26-,27-,28+,29+,30-/m0/s1

HIDE SMILES / InChI

Molecular Formula C30H48O4
Molecular Weight 472.7009
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Hederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κB. Hederagenin exhibits multiple pharmacological activities in the treatment of hyperlipidemia, antilipid peroxidation, antiplatelet aggregation, liver protection, antidepression, anti-inflammation.

CNS Activity

Curator's Comment:: The pharmacokinetics results indicated that hederagenin could pass through the blood-brain barrier. Demonstrated in rats.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.39 µM [IC50]
40.6 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats.
2015
Hederagenin, a major component of Clematis mandshurica Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice.
2015 Dec
Patents

Patents

Sample Use Guides

Hederagenin, dissolved in 40% polyethylene glycol, was administered orally to mice at doses of 5 or 30 mg/kg/day for four consecutive days.
Route of Administration: Oral
Treatment with hederagenin (10, 30 and 100uM) resulted in inhibited levels of protein expression of lipopolysaccharide-stimulated iNOS, COX-2, and NF-κB as well as production of NO, PGE2, TNF-α, IL-1β, and IL-6 induced by lipopolysaccharide in RAW 264.7 cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 05:56:37 UTC 2021
Edited
by admin
on Sat Jun 26 05:56:37 UTC 2021
Record UNII
RQF57J8212
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HEDERAGENIN
MI  
Common Name English
ASTRANTIAGENIN E
Common Name English
OLEAN-12-EN-28-OIC ACID, 3,23-DIHYDROXY-, (3.BETA.,4.ALPHA.)-
Common Name English
OLEAN-12-EN-28-OIC ACID, 3.BETA.,23-DIHYDROXY-
Common Name English
CAULOSAPOGENIN
Common Name English
HEDERAGENIC ACID
Common Name English
HEDERAGENIN [MI]
Common Name English
HEDERAGENIN, (+)-
Common Name English
HEDERAGENOL
Common Name English
HEDERAGENINE
Common Name English
NSC-24954
Code English
Code System Code Type Description
FDA UNII
RQF57J8212
Created by admin on Sat Jun 26 05:56:37 UTC 2021 , Edited by admin on Sat Jun 26 05:56:37 UTC 2021
PRIMARY
WIKIPEDIA
HEDERAGENIN
Created by admin on Sat Jun 26 05:56:37 UTC 2021 , Edited by admin on Sat Jun 26 05:56:37 UTC 2021
PRIMARY
ECHA (EC/EINECS)
207-369-9
Created by admin on Sat Jun 26 05:56:37 UTC 2021 , Edited by admin on Sat Jun 26 05:56:37 UTC 2021
PRIMARY
RXCUI
2045115
Created by admin on Sat Jun 26 05:56:37 UTC 2021 , Edited by admin on Sat Jun 26 05:56:37 UTC 2021
PRIMARY
CAS
465-99-6
Created by admin on Sat Jun 26 05:56:37 UTC 2021 , Edited by admin on Sat Jun 26 05:56:37 UTC 2021
PRIMARY
PUBCHEM
73299
Created by admin on Sat Jun 26 05:56:37 UTC 2021 , Edited by admin on Sat Jun 26 05:56:37 UTC 2021
PRIMARY
MERCK INDEX
M5929
Created by admin on Sat Jun 26 05:56:37 UTC 2021 , Edited by admin on Sat Jun 26 05:56:37 UTC 2021
PRIMARY Merck Index
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Structure given in reference is incorrect as per name given in Scifinder